It is, therefore, crucial to develop inhibitors of the PI3K/AKT/mTOR pathway with rational targets in mind, such as PTEN loss and PIK3CA-activating mutations, in combination with downstream molecular marker evaluations, which is more likely to yield success than current approaches in CRC treatment. This evidence concerns the gene MTOR and colorectal carcinoma.